<img src="https://ml.globenewswire.com/Resource/Download/8fec8de1-1a2e-4f6c-a679-fc43002276ba?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Madrigal_Logo.jpg" alt="Madrigal Pharmaceuticals, Inc."/>CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals <a href="https://www.globenewswire.com/Tracker?data=9kYfnAnWO15nT0MXbJ-3zSVKZexPxKLoy17foQrLY45MXr8Rtd0X58GlioPW-FhfhFaTMswKixXfIwITm6WqhijHHol8V5O1gCSQ6cGreficEP9dZqRMl3xXoQqFldr9" rel="nofollow" target="_blank" title="website">website</a>. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hours after the live webcast. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit <a href="https://www.globenewswire.com/Tracker?data=eYpxaKSanBhoDOQC5uIM1Wpwo8iatX7yJ7-niqk1YMb8xgivnMD_r0ypYrEjou2p0y79sgHPUj-RTBiKzUcotHx7qnyJiP5tPV2qHIomoEqnUfuAPaKd6RvmUsjEAXL1rK86796PS6vUdMZJxu3WtKVxicOY8GlPbxaTauMI8hI3D9xDLz4B96ZSkC25-tKlh3qmIv-Vmovk9TJUvj7uOHCCeZhMpUxhzLvH2g82z7flNmbhHY3pCOh-cS8uuIZMAtwzJseGHivQKmvhpiaMletnIiA1hUx6TQrGiQf4WKL5iGEyJkdZy-uDMxVqx4OenGFkpDP4zPaUi4bUt6qauL2rfDSbh_rlD2s5z6OANmgHb1XxCMIVqGuxaGDbI5LaQQ6pDLtzKBrpQkHfGcWWgIEk24U7d8YaljwpAGdgp54A9bysIqtoceru3nVKpjpu-j5_YtwKycBsN3azuVVZFeb1aaoykMvW-sllKgopcZJTVyBv_8iwEOh2OU7MbhAf" rel="nofollow" target="_blank" title="www.madrigalpharma.com">www.madrigalpharma.com</a>. Investor Contact Tina Ventura, Madrigal Pharmaceuticals, Inc., <a href="https://www.globenewswire.com/Tracker?data=LsV5kOEm8o98dk5Ec2AyzQsYqDMYd3H9h4vqtgtarsImmWD94AOvASzb_S0EVbCkcWAlwgC9T8mSaDeOayJdNBILu_oXqbjSiwKHosczlgM=" rel="nofollow" target="_blank" title="IR@madrigalpharma.com">IR@madrigalpharma.com</a> Media Contact Christopher Frates, Madrigal Pharmaceuticals, Inc., <a href="https://www.globenewswire.com/Tracker?data=vVZe6NZ0oqri4y6ieU9Ge0zwNluhFJl8BYRwbGgGFiWuFW3fmPGqeIsB01i8oUzPwPPjJ8HGWqX2P-0KG78As5dVfAhsD1mCRwsM16Y0bp7SlKaIEG3pJlTy0Z4u_VO2" rel="nofollow" target="_blank" title="media@madrigalpharma.com">media@madrigalpharma.com</a> <img alt="" src='https://ml.globenewswire.com/media/OWQ1YzNlYTAtOTg1NS00ZjA0LWEzNjYtODRjMGEwODBlMmIyLTEwMTc3ODYtMjAyNi0wNy0xNi1lbg==/tiny/Madrigal-Pharmaceuticals-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn